Q-omics provides the consensus-scored CERKL profile across patient tissues and cancer cell-line models. CERKL expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CERKL is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, CERKL RNA expression shows 18,570 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KICH, and UVM as cancer lineages where CERKL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CERKL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CERKL survival associations across molecular data types. CERKL RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CERKL RNA expression–survival associations across cancer types. High CERKL expression shows unfavorable associations in UVM and DLBC, but favorable associations in HNSC, LUAD, SKCM and SCLC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CERKL RNA expression.
This table summarizes CERKL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CERKL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CERKL shows lower tumor expression in KICH, KIRP and LUSC and higher tumor expression in STAD, BRCA and HNSC. The KICH box plot shows higher CERKL RNA expression in normal versus tumor tissue (log2 FC = −2.470, t-test p < 0.001).
This table shows molecular features associated with CERKL in patient tissues and cancer cell lines. In patient samples, CERKL shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CERKL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
